Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a pioneering biotechnology firm headquartered in the United States, focuses on developing innovative therapies for serious medical conditions. Founded in 2000, the company has made significant strides in the fields of regenerative medicine and cell therapy, particularly in the treatment of cardiovascular diseases and Duchenne muscular dystrophy (DMD). Capricor's flagship product, CAP-1002, is a unique allogeneic cardiosphere-derived cell therapy that aims to improve heart function in patients with advanced heart failure. The company has garnered attention for its robust clinical trial results and commitment to advancing therapeutic options in underserved patient populations. With a strong market position and a dedication to scientific excellence, Capricor Therapeutics continues to lead the way in transforming the landscape of regenerative medicine.
DitchCarbon Score
How does Capricor Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Capricor Therapeutics, Inc.'s score of 18 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Capricor Therapeutics, Inc.'s reported carbon emissions
Capricor Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is challenging to assess their climate impact or sustainability efforts. However, as a company in the biotechnology sector, Capricor is likely aware of the growing importance of addressing climate change and may be exploring strategies to align with industry standards. As the landscape of corporate climate commitments evolves, it will be essential for Capricor to establish clear targets and transparency in their environmental practices to meet stakeholder expectations and contribute to global sustainability goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Capricor Therapeutics, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
